Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C8H15NO3 |
| Molecular Weight | 173.2096 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C[C@H](NC(C)=O)C(O)=O
InChI
InChIKey=WXNXCEHXYPACJF-ZETCQYMHSA-N
InChI=1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12)/t7-/m0/s1
DescriptionCurator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/13523909 | https://www.ncbi.nlm.nih.gov/pubmed/27083881 | http://adisinsight.springer.com/drugs/800029130
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/13523909 | https://www.ncbi.nlm.nih.gov/pubmed/27083881 | http://adisinsight.springer.com/drugs/800029130
L-Acetylleucine is enantiomer of Acetylleucine that used in the treatment of vertigo and cerebellar ataxia. The N-acetyl-L-leucine isomer is the active part of the racemate component since it induces a significant acceleration of the vestibular compensation process similar and even better than that observed under treatment with the racemate component only. Acetylleucine was aggressively marketed in France for vertigo. It may act as a precursor of a peptidic neuromediator responsible for activation of vestibular afferents. It may also have ‘anticalcium’ properties on neurotransmission. Pierre Fabre conducted clinical studies of L-Acetoleusine for Vertigo and Dizzinesstherapy. However, all clinical studies were discontinued
CNS Activity
Originator
Approval Year
Sample Use Guides
On average 3 to 4 tablets (1 tablet = 500mg DL-Acetylleucine) in two doses morning and evening.
Route of Administration:
Oral
Intracellular recordings were obtained from 33 neurons within the MVN with 3 M K-acetate-containing glass microelectrodes (70±120 MW), taking the border of the fourth ventricle as a landmark. The mean activity of each neuron and the effects of acetyl-DL-leucine were established by monitoring the membrane potential, the membrane resistance and the spontaneous firing rate of the cell. Since in control medium, most MVN neurons display a spontaneous, regular discharge, their `mean membrane potential' was defined as the membrane potential value measured in the middle of each interspike interval. Acetyl-DL-leucine was also applied to 30 MVN neurons recorded extracellularly, using 2 M NaCl-containing glass microelectrodes (2±8 MW). Data obtained through an Axoclamp 2A amplifier (Axon Instruments, Foster City, California, USA) were followed online on a paper chart recorder
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
914022
Created by
admin on Sat Dec 16 08:23:38 GMT 2023 , Edited by admin on Sat Dec 16 08:23:38 GMT 2023
|
||
|
FDA ORPHAN DRUG |
836121
Created by
admin on Sat Dec 16 08:23:38 GMT 2023 , Edited by admin on Sat Dec 16 08:23:38 GMT 2023
|
||
|
FDA ORPHAN DRUG |
855721
Created by
admin on Sat Dec 16 08:23:38 GMT 2023 , Edited by admin on Sat Dec 16 08:23:38 GMT 2023
|
||
|
FDA ORPHAN DRUG |
870222
Created by
admin on Sat Dec 16 08:23:38 GMT 2023 , Edited by admin on Sat Dec 16 08:23:38 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
70912
Created by
admin on Sat Dec 16 08:23:38 GMT 2023 , Edited by admin on Sat Dec 16 08:23:38 GMT 2023
|
PRIMARY | |||
|
58270
Created by
admin on Sat Dec 16 08:23:38 GMT 2023 , Edited by admin on Sat Dec 16 08:23:38 GMT 2023
|
PRIMARY | |||
|
206316
Created by
admin on Sat Dec 16 08:23:38 GMT 2023 , Edited by admin on Sat Dec 16 08:23:38 GMT 2023
|
PRIMARY | |||
|
17786
Created by
admin on Sat Dec 16 08:23:38 GMT 2023 , Edited by admin on Sat Dec 16 08:23:38 GMT 2023
|
PRIMARY | |||
|
E915HL7K2O
Created by
admin on Sat Dec 16 08:23:38 GMT 2023 , Edited by admin on Sat Dec 16 08:23:38 GMT 2023
|
PRIMARY | |||
|
214-706-3
Created by
admin on Sat Dec 16 08:23:38 GMT 2023 , Edited by admin on Sat Dec 16 08:23:38 GMT 2023
|
PRIMARY | |||
|
1010081
Created by
admin on Sat Dec 16 08:23:38 GMT 2023 , Edited by admin on Sat Dec 16 08:23:38 GMT 2023
|
PRIMARY | |||
|
E915HL7K2O
Created by
admin on Sat Dec 16 08:23:38 GMT 2023 , Edited by admin on Sat Dec 16 08:23:38 GMT 2023
|
PRIMARY | |||
|
1188-21-2
Created by
admin on Sat Dec 16 08:23:38 GMT 2023 , Edited by admin on Sat Dec 16 08:23:38 GMT 2023
|
PRIMARY | |||
|
DTXSID6045870
Created by
admin on Sat Dec 16 08:23:38 GMT 2023 , Edited by admin on Sat Dec 16 08:23:38 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
